President Moon Jae-in said it is important to develop a corona vaccine and treatment in-house, and said the government will not spare support until the development is definitely successful.
President Moon said, "We need to further enhance our ability to develop treatments and vaccines in preparation for infectious diseases that will come again after the coronavirus," at a meeting at SK Bioscience, a corona vaccine developer located in Seongnam, Gyeonggi-do, on the 15th.
He emphasized that "in-house development is essential to accumulate development experience, and it is also necessary to reduce supply prices as experienced during the swine flu."
President Moon said, "The government will spare no support until the end until the development is definitely successful," he said. "Even if another country succeeds in development first and our country can import, we have a willingness to succeed in self-development until the end." .
The researchers encouraged the researchers, saying, "Amid fierce competition among global companies, Korea is also making significant results in the development of vaccines and treatments."
"We have been in consultation with global vaccine companies," said President Moon. "If the development process goes smoothly, we can expect full-scale production of the treatment within this year and the development of the vaccine by next year," said Moon.
He also said, "We are steadily progressing the plan to secure vaccines for a total of 30 million people, which accounts for 60% of our people."
After visiting the vaccine development site, President Moon expressed expectations, saying, "I have new feelings and confidence in our technology."
President Moon said, "SK Bioscience is developing a safe and effective synthetic antigen vaccine, and is starting a clinical trial this month." "Celltrion is developing an antibody treatment, and in the final phase of the clinical trial, phases 2 and 3 are simultaneously conducted. I introduced it."
He also said, "We look forward to using the blood treatment system developed by Genexine and Green Cross within this year."
President Moon said that the risk of the company was high as it took time and enormous cost to develop vaccines and treatments. After the government provided 210 billion won this year, the next year's budget increased 19 percent to 260 billion won.
In addition, he said that it will actively support clinical trials by operating a national infectious disease clinical trial center linking three base hospitals and 17 hospitals nationwide, and that it will also support overseas clinical trials at the government level.
President Moon said, "I believe that K-Bio will once again become hope and pride for us following K-Defense and the government will be with you until the end."
(Photo = Yonhap News)